Innate Pharma SA Class A

As of June 30, 2026, Innate Pharma SA Class A carries a market capitalization of 151.75M, placing it among publicly traded companies globally. Its enterprise value stands at 161.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Innate Pharma SA Class A's next confirmed earnings release is scheduled for March 25, 2027.

As of June 30, 2026, Innate Pharma SA Class A has 93.90M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Innate Pharma SA Class A maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Innate Pharma SA Class A's stock has declined approximately 26.30% over the past 52 weeks. The 50-day moving average sits at 1.61, while the 200-day moving average is 1.50.

As of June 30, 2026, Innate Pharma SA Class A holds 10.90M in cash and equivalents against 20.21M in total debt, resulting in a net debt position of 13.61M. Total book value stands at -40.51M, with working capital of -13.26M providing operational flexibility.